Abnormal Circulating Interleukin 23 Concentration C5676765
IL-23 is a pro-inflammatory cytokine important in autoimmune responses. Linked to psoriasis and inflammatory bowel disease. Often treated with targeted immunosuppressive therapies.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Chest discomfort
Pressure, tightness, or pain in the chest area that may be intermittent.
Seek immediate emergency care if chest pain is severe, crushing, or accompanied by shortness of breath, sweating, or arm pain
High fever
Elevated body temperature above 101°F (38.3°C) that may be persistent or recurring.
Seek immediate medical attention for fever above 103°F (39.4°C) or fever accompanied by confusion or difficulty breathing
Persistent fatigue
(constitutional)Generalized tiredness and lack of energy that does not improve with rest, often accompanied by malaise.
Frequency: 70-80% of patients
Skin rash
(dermatologic)Red, scaly patches of skin typically appearing on elbows, knees, scalp, and lower back, often itchy.
Frequency: 65-75% of patients
Abdominal pain
(gastrointestinal)Recurring abdominal discomfort or cramping, often associated with digestive disturbances.
Frequency: 40-50% of patients
Joint pain and stiffness
(musculoskeletal)Pain, swelling, and morning stiffness in joints, particularly affecting the spine and peripheral joints.
Frequency: 35-45% of patients
Diarrhea
(gastrointestinal)Frequent loose or watery stools, which may be chronic and intermittent.
Frequency: 30-40% of patients
Shortness of breath
(respiratory)Difficulty breathing or feeling breathless, especially during physical activity.
Frequency: 15-20% of patients
Headache
(neurologic)Persistent or recurrent headaches that may range from mild to severe.
Frequency: 10-15% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Anti-IL-23 biologic agents
Targeted biologic therapy that specifically blocks interleukin-23 signaling pathways, reducing Th17 cell activation and associated inflammatory responses in autoimmune conditions.
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Anti-inflammatory diet modification
Implementation of an anti-inflammatory dietary pattern emphasizing omega-3 fatty acids, colorful vegetables, and avoiding processed foods to help modulate immune responses.
Additional treatment options
Conventional immunosuppressants
Systemic immunosuppressants such as methotrexate may be used when biologics are contraindicated or as adjunct therapy for enhanced disease control.
medicationStress management and relaxation therapy
Cognitive-behavioral techniques and relaxation training to reduce stress-induced immune dysregulation, as psychological stress can exacerbate inflammatory cytokine patterns.
psychologicalRegular cytokine and inflammatory marker surveillance
Periodic laboratory monitoring of IL-23 levels along with CRP and ESR to assess disease progression and treatment response over time.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Circulating Interleukin 23 Concentration C5676765?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Elmets CA, Leonardi CL, Goffe BS, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113.
Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Crohn's Disease and Ulcerative Colitis. J Crohn's Colitis. 2020;14(1):4-22.
K�fly K, Korn T. IL-23 and IL-12/23 in immunity to fungi. J Autoimmun. 2019;104:102314.
Chen L, Wang H, Wang J, et al. Circulating IL-23 levels in patients with autoimmune diseases: A systematic review and meta-analysis. Autoimmun Rev. 2021;20(8):102882.
Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2019;380(14):1315-1326.
American College of Rheumatology. Guidelines for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(5):640-656.
Teng MWL, Bowman EP, McElhee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2018;24(7):987-1001.
European Task Force on Atopic Dermatitis. European consensus statement on atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(11):2457-2475.
Medication Comparisons
Compare medications used to treat Abnormal Circulating Interleukin 23 Concentration C5676765. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy